Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Soochow UniversityActive in the last 2 years

Dongming Zhu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5502-9036; OpenAlex author ID A5102023719. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 10

  1. ZKSCAN5 activates LAPTM5 expression by recruiting SETD7 to promote metastasis in pancreatic ductal adenocarcinoma. Last author DOI 10.14670/hh-18-678↗
  2. Long Noncoding RNA LINC00578 Inhibits Ferroptosis in Pancreatic Cancer via Regulating SLC7A11 Ubiquitination. Co-author DOI 10.1155/2023/1744102↗
  3. Integrative analysis of TNFRSF6B as a potential therapeutic target for pancreatic cancer. Co-author DOI 10.21037/jgo-21-303↗
  4. Nigericin Suppresses the Wnt/β-catenin Signaling in Pancreatic Cancer through Targeting pre-miR-374b-PRKCA/HBP1 Axis Co-author DOI 10.21203/rs.3.rs-52126/v1↗
  5. HIF-2α promotes the formation of vasculogenic mimicry in pancreatic cancer by regulating the binding of Twist1 to the VE-cadherin promoter. First author DOI 10.18632/oncotarget.17999↗
  6. Methylation of BNIP3 in pancreatic cancer inhibits the induction of mitochondrial-mediated tumor cell apoptosis. Co-author DOI 10.18632/oncotarget.18736↗
  7. HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer. Co-author DOI 10.1186/s13046-016-0298-y↗
  8. The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer. Co-author DOI 10.2147/ott.s66809↗
  9. Expression levels of microRNA-375 in pancreatic cancer. Co-author DOI 10.3892/br.2013.88↗
  10. MicroRNA-375 is downregulated in pancreatic cancer and inhibits cell proliferation in vitro. Co-author DOI 10.3727/096504013x13589503482734↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jian Zhou · 7 shared papers, 2012–2023 · strength 0.58
  2. Dechun Li · 6 shared papers, 2012–2017 · strength 0.32
  3. Haoran Li · 2 shared papers, 2021–2023 · strength 0.31
  4. Yuchen Tang · 2 shared papers, 2021–2023 · strength 0.31
  5. Yong Yang · 1 shared paper, 2024 · strength 0.26
  6. Jian Yang · 3 shared papers, 2016–2017 · strength 0.20
  7. Yi Zhang · 3 shared papers, 2016–2017 · strength 0.20
  8. Jian Yang · 1 shared paper, 2023 · strength 0.18
  9. Jun Yao · 1 shared paper, 2023 · strength 0.18
  10. Qiaoming Zhi · 2 shared papers, 2014–2020 · strength 0.15
  11. Zixiang Zhang · 3 shared papers, 2012–2017 · strength 0.15
  12. Ye Li · 2 shared papers, 2016–2017 · strength 0.13
  13. Yijun Wei · 1 shared paper, 2021 · strength 0.13
  14. Chen Zhang · 1 shared paper, 2021 · strength 0.13
  15. Shiduo Song · 3 shared papers, 2012–2014 · strength 0.11
  16. Wei Li · 1 shared paper, 2020 · strength 0.11
  17. Ye Xu · 1 shared paper, 2020 · strength 0.11
  18. Min Jiang · 1 shared paper, 2020 · strength 0.11
  19. Zhihua Xu · 1 shared paper, 2020 · strength 0.11
  20. Hua Zhao · 2 shared papers, 2013–2014 · strength 0.08
  21. Yan Chen · 1 shared paper, 2014 · strength 0.04
  22. Yuting Kuang · 1 shared paper, 2014 · strength 0.04
  23. Jing Sun · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.